CAR T-cell therapy in large B cell lymphoma Conference Paper
| Authors: | Boardman, A. P.; Salles, G. |
| Title: | CAR T-cell therapy in large B cell lymphoma |
| Conference Title: | 17th International Conference on Malignant Lymphoma |
| Abstract: | CD19-targeted chimeric antigen receptor (CAR) T-cells have revolutionized the treatment of lymphoid malignancies, including large B cell lymphoma (LBCL). Following seminal early phase multicenter clinical trials published between 2017 and 2020, three CD19-CAR T-cell products received FDA and EMA approval designations in lymphoma in the third-line setting, paving the way for follow-up studies in the second-line. Meanwhile, investigations into the applications of CAR T-cell therapy have further broadened to treating high-risk patients even prior to completion of first-line conventional chemo-immunotherapy. Furthermore, as early trials excluded patients with central nervous system involvement with lymphoma, several studies have recently shown promising efficacy of CD19-CAR T-cells in primary and secondary CNS lymphoma. Here we provide a detailed overview on clinical data supporting the use of CAR T-cells in patients with LBCL. © 2023 John Wiley & Sons Ltd. |
| Keywords: | b-cell lymphoma; primary cns lymphoma (pcnsl); cd19; diffuse large b-cell lymphoma (dlbcl); non-hodgkin lymphoma (nhl); chimeric antigen receptor (car) t cell; autologous stem cell transplantation (asct); secondary cns lymphoma (scnsl) |
| Journal Title | Hematological Oncology |
| Volume: | 41 |
| Issue: | Suppl. 1 |
| Conference Dates: | 2023 Jun 13-17 |
| Conference Location: | Lugano, Switzerland |
| ISBN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-06-01 |
| Start Page: | 112 |
| End Page: | 118 |
| Language: | English |
| DOI: | 10.1002/hon.3153 |
| PUBMED: | 37294963 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work